霍奇金淋巴瘤患者自体干细胞移植后早期复发结局近年有所改善
分析1781例2006至2017年间首次自体干细胞移植后复发的成人霍奇金淋巴瘤患者,复发后4年总生存率从2006-2008年的32%持续升至2015-2017年的63%(p=0.001),改善主要见于移植后12个月内早期复发者(p=0.01);维布妥昔单抗、检查点抑制剂及二次移植使用者的4年总生存率分别为55%、48%和55%。
要点
- 复发后4年总生存率从2006-2008年的32%升至2015-2017年的63%(p=0.001)。
- 生存改善主要见于自体移植后12个月内早期复发患者(p=0.01)。
- 维布妥昔单抗、检查点抑制剂及二次移植后4年总生存率分别为55%、48%和55%。
核心结论
- 移植后复发后的结局近年显著改善,尤其是早期复发患者。
- 这些大规模真实世界数据可作为该领域未来研究的基准。
研究设计与样本
- 分析1781例2006至2017年间首次自体干细胞移植后复发的成人霍奇金淋巴瘤患者。
主要发现
- 复发后4年总生存率从2006-2008年复发的32%持续升至2015-2017年复发的63%(p=0.001)。
- 生存改善主要见于自体移植后12个月内早期复发患者(p=0.01)。
- 多因素分析中,较近年份复发和移植至复发间隔较长者总生存较好,而年龄较大、体能状态差、巨块病变、结外病变及复发时存在B症状与总生存较差相关。
- 维布妥昔单抗、检查点抑制剂和二次移植分别用于233、91和330例患者,其使用后4年总生存率分别为55%、48%和55%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hodgkin lymphoma (HL) patients who relapse after autologous-stem-cell- transplantation (auto-SCT) have traditionally had a poor prognosis. We analyzed 1781 adult HL patients who relapsed between 2006 and 2017 after a first auto-SCT. The 4-year overall survival (OS) after relapse continuously increased from 32% for patients relapsing in 2006-2008, to 63% for patients relapsing in 2015-2017 (p = 0.001). The improvement over time was predominantly noted in patients who had an early relapse (within 12 months) after auto-SCT (p = 0.01). On multivariate analysis, patients who relapsed in more recent years and those with a longer interval from transplant to relapse had a better OS, whereas increasing age, poor performance status, bulky disease, extranodal disease and presence of B symptoms at relapse were associated with a worse OS. Brentuximab vedotin (BV), checkpoint inhibitors (CPI) and second transplant (SCT2; 86% allogeneic) were used in 233, 91 and 330 patients respectively. The 4-year OS from BV, CPI, and SCT2 use was 55%, 48% and 55% respectively. In conclusion, the outcome after post-transplant relapse has improved significantly in recent years, particularly in the case of early relapse. These large-scale real-world data can serve as benchmark for future studies in this setting.
引用
- Bazarbachi A, Boumendil A, Finel H, et al. The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years. Leukemia. 2022. PMID: 35414657. doi:10.1038/s41375-022-01563-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。